



# Oncothermia treatment of lung carcinomas

Dr. Seok Jun Haam

Department of Thoracic & Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea; [hamsi@yumc.yonsei.ac.kr](mailto:hamsi@yumc.yonsei.ac.kr)

## Objective

Advanced lung carcinomas were studied. Oncothermia was combined with various chemotherapies and radiotherapy. Our objective was to obtain reliable data of lung cancer treatment with oncothermia. Results are interim, the study is in progress.





## Method

Study was started in August 2008, and was sequentially evaluated in December 2009 (n=66) and September 2010 (n=118), retrospectively.





Number of patients till September 2010: n=118 (70/48 m/f)

Oncothermia was provided with device EHY-2000, 60 min in all sessions, using electrode of 30 cm diameter.

In first period 54.5% in the second one 64.4% was in advanced stages, and additionally 21.2% and 33% had recurrence or metastases, respectively. The other stages were only 24.2% and 9% in the investigation sequences respectively.





We studied only the cases with eligible number of sessions, excluding those who had not such number (less than 12 sessions) of the treatments. Numbers of included patients are n=38 and n=79, respectively.




## Results

We had measured the local clinical response only, the survival analysis could be done later. The local data shows improvement (CR+PR) 47.4% and 46.8%, NC 31.6% & 35.4%; PD 15.8% & 15.2%; n.d. 5.2% & 2.5% in first and second sequences of the study, respectively. Regarding the advanced and relapsed cases, the overall local response-rate (CR+PR+NC) is 79% and 82.2%.


**No complications were observed related to oncothermia.**



**Aug. 2008. → Dec. 2009**




**Aug. 2008. → Sep. 2010**



## Terminations

Oncothermia treatment process was terminated for 37 patients (31.4%) due to various reasons. The interruption was caused by:



## Conclusion

Benefits	Disadvantages
<ul style="list-style-type: none"> <li>Easy to treat.</li> <li>No vomiting, no body weakness, no hair loss no complications.</li> <li>Effective pain-reduction</li> </ul>	<ul style="list-style-type: none"> <li>The expensive cost of treatment</li> <li>Does not seem to work immediately</li> <li>Shortness of breath due to pleural effusion at the attitude is difficult to lay</li> </ul>

Oncothermia treatment has feasibility to treat advanced and relapsed cases of lung-cancer. For evidences a perspective, randomized study, and the overall survival end-point is desired. The further work is in progress.